AMLX vs APUS: Side-by-Side Comparison
Compare Amylyx Pharmaceuticals Inc (AMLX) and Apimeds Pharmaceuticals US Inc (APUS) side by side: market cap USD 2.03B vs USD 13.58M. Financials, growth and model signals on Bullrun.
| Metric | AMLX | APUS |
|---|---|---|
| Company | Amylyx Pharmaceuticals Inc | Apimeds Pharmaceuticals US Inc |
| Country / Exchange | United States · NASDAQ | United States · NYSE MKT |
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers-Specialty & Generic | Drug Manufacturers-Specialty & Generic |
| Market cap | USD 2.03B | USD 13.58M |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Valuation model | — | — |
| Revenue (FY2025) | USD 0 | — |
| Revenue growth YoY | -100.0% | — |
| Net income | USD -144.74M | USD -6.00M |
| Gross margin | — | — |
| Diluted EPS | -1.53 | -0.55 |